ROVI

ROVI is a specialized pharmaceutical company engaged in the research, development, manufacturing and marketing of pharmaceutical products. 

Its operations encompass the marketing of both its own and licensed products and the provision of services, such as production, filling, packaging and running clinical trials for other companies.

On 7th of March, 2017. Laboratorios Farmacéuticos ROVI, S.A received the positive outcome of the marketing authorization application of a low molecular weight heparin (enoxaparin biosimilar) in twenty-six countries of the European Union (Lithuania not included). The Decentralised procedure (DCP) used Germany as Reference Member State. The first country in Europe where Enoxaparin biosimilar has been launched has been Germany in September 2017 and in March 2018 was launched in the UK market.

More than 70 years researching and improving health, find out our major milestones

 

1946

Foundation of the Company

 

1981

Beginning of research into low-molecular-weight heparins

 

1998

Launch of Bemiparin (ROVI's own development LMWH) on the Spanish Market

 

2002

Internationalization of ROVI following
approval of Bemiparin outside Spain

 

2003

Increased International coverage
to 56 countries

 

2006

Construction of the Granada R&D&i
centre and plant

 

2012

FDA certification of the
injectables plant

 

2014

Registration process for an
enoxaparin biosimilar with the EU

 

2015

Adquisition of the new injectables plant
in San Sebastián de los Reyes

 

2017

Successful completion of the
procedure to apply for authorization to market
an enoxaparin biosimilar in 26 EU countries

ISM

With our Biosimilar
Enoxaparin, ROVI will increase its presence in Europe, United States and emerging countries

The development of a biosimilar of enoxaparin is a logical evolution of ROVI business. With the biosimilar of enoxaparin, ROVI is aiming to become one of the European top players in a €1Bn market. ROVI will increase its footprint also in emerging markets with a potential market of Eur 0.5Bn sales. 
ROVI has a significant competitive advantage in the Enoxaparin market thanks to its vertical integration.

LEARN MORE ABOUT ROVI WATCHING THE VIDEO